Table 1.
Mutation | Type | Dasatinib | Dasatinib IC50 (nM) | |
---|---|---|---|---|
BCPAP | BRAF (V600E) | Papillary | Sensitive | 19 |
8505C | BRAF (V600E) | Anaplastic | Resistant | >3000 |
Cal62 | KRAS (G12R) | Anaplastic | Sensitive | 66 |
C643 | HRAS (G13R) | Anaplastic | Resistant | >3000 |
T238 | BRAF (V600E)/PIK3CA E542K | Anaplastic | Resistant | >3000 |
THJ16T | PIK3CA E545K | Anaplastic | Intermediate | 677 |
Cell lines are categorized based on mutation status, tumor subtype, and sensitivity or resistance to dasatinib. Sensitivity is based on an IC50 value <90 nM, as determined by CellTiter-Glo assay (Promega; Fig. 1a)